Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial.
Journal
Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
07
07
2022
accepted:
18
07
2022
pubmed:
21
9
2022
medline:
4
11
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
The aim of this study was to evaluate the effect of a novel, oral, modified-release formulation of the lipase inhibitor orlistat and the glucosidase/amylase inhibitor acarbose (denoted EMP16) on relative body weight after 26 weeks compared with placebo. The randomized, double-blind, placebo-controlled trial had a 26-week treatment period, with dose escalation up to 6 weeks. Participants, adults between ages 18 and 75 years, with BMI ≥30 kg/m Of 156 randomized participants, 149 constituted the intention-to-treat population. The mean (95% CI) estimated treatment difference to placebo in relative weight loss after 26 weeks in the intention-to-treat population was -4.70% (-6.16% to -3.24%; p < 0.0001) with EMP16-120/40 and -5.42% (-6.60% to -4.24%; p < 0.0001) with EMP16-150/50. This trial indicates that orlistat and acarbose can be successfully combined in a modified-release formulation to provide efficacious weight loss with no unexpected safety issues. EMP16 may be a promising candidate among other medications for improved weight management.
Identifiants
pubmed: 36123783
doi: 10.1002/oby.23557
pmc: PMC9826204
doi:
Substances chimiques
Orlistat
95M8R751W8
Acarbose
T58MSI464G
Anti-Obesity Agents
0
Lactones
0
Enzyme Inhibitors
0
Banques de données
EudraCT
['2019-004545-32']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2222-2232Informations de copyright
© 2022 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
Références
Eat Weight Disord. 2006 Dec;11(4):e127-32
pubmed: 17272944
Ann Med. 2001 Jul;33(5):350-7
pubmed: 11491194
Diabetes Obes Metab. 2005 May;7(3):254-62
pubmed: 15811142
Korean J Anesthesiol. 2017 Apr;70(2):144-156
pubmed: 28367284
Gut. 1996 Jun;38(6):916-9
pubmed: 8984033
Nat Rev Drug Discov. 2022 Mar;21(3):201-223
pubmed: 34815532
Clin Pharmacol Drug Dev. 2021 Oct;10(10):1242-1247
pubmed: 33580745
J Biopharm Stat. 2016;26(1):30-6
pubmed: 26418188
Eur J Clin Pharmacol. 1998 Apr;54(2):125-32
pubmed: 9626916
J Hypertens. 2012 Dec;30(12):2338-44
pubmed: 23032140
Expert Opin Drug Saf. 2009 Nov;8(6):727-44
pubmed: 19998527
Obesity (Silver Spring). 2022 Nov;30(11):2222-2232
pubmed: 36123783
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Int J Clin Pract. 2014 Nov;68(11):1318-32
pubmed: 24853116
Lancet. 2022 Jan 15;399(10321):259-269
pubmed: 34895470
Rev Endocr Metab Disord. 2021 Dec;22(4):763-775
pubmed: 33123893
Am J Clin Nutr. 2004 Dec;80(6):1461-8
pubmed: 15585756
BMC Public Health. 2016 Jul 30;16:676
pubmed: 27475752
Qual Life Res. 1998 Jan;7(1):75-83
pubmed: 9481153
Clin Nutr ESPEN. 2021 Apr;42:90-92
pubmed: 33745626
N Engl J Med. 2022 Jul 21;387(3):205-216
pubmed: 35658024
J Clin Endocrinol Metab. 2008 Oct;93(10):3995-8
pubmed: 18647814
Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G752-63
pubmed: 11518688
Diabetes Care. 2004 Jan;27(1):155-61
pubmed: 14693982
JAMA. 2016 Jun 14;315(22):2424-34
pubmed: 27299618
Lancet. 2017 Apr 8;389(10077):1399-1409
pubmed: 28237263
Obes Rev. 2010 Mar;11(3):251-70
pubmed: 20122136
Lancet. 2009 Nov 7;374(9701):1606-16
pubmed: 19853906
Obes Sci Pract. 2020 Feb 07;6(3):313-323
pubmed: 32523721